کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2773129 | 1567899 | 2015 | 9 صفحه PDF | دانلود رایگان |
• Osteopontin is significantly increased in the CSF of NMO patients.
• Osteopontin is markedly elevated in the cerebral white matter of NMO patients.
• NMO osteopontin is produced by astrocytes, neurons, oligodendroglia, and macrophages.
• Interaction of NMO osteopontin with integrin αvβ3 promotes macrophage chemotaxis.
• NMO osteopontin promotes macrophage chemotaxis by activating PI3K and MEK1/2.
BackgroundNeuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that predominantly affects the optic nerves and spinal cord. Although NMO has long been considered a subtype of multiple sclerosis (MS), the effects of interferon-β treatment are different between NMO and MS. Recent findings of NMO-IgG suggest that NMO could be a distinct disease rather than a subtype of MS. However, the underlying molecular mechanism of NMO pathology remains poorly understood.MethodsOPN in the cerebrospinal fluid and brain of patients with NMO and with MS, as well as of patients with other neurologic disease/idiopathic other neurologic disease was examined using Western blotting, ELISA, immunohistochemistry and Boyden chamber.ResultsHere we show that osteopontin is significantly increased in the cerebrospinal fluid of NMO patients compared with MS patients. Immunohistochemical analyses revealed that osteopontin was markedly elevated in the cerebral white matter of NMO patients and produced by astrocytes, neurons, and oligodendroglia as well as infiltrating macrophages. We also demonstrate that the interaction of the cerebrospinal fluid osteopontin in NMO patients with integrin αvβ3 promoted macrophage chemotaxis by activating phosphoinositide 3-kinase and MEK1/2 signaling pathways.ConclusionThese results indicate that osteopontin is involved in NMO pathology.General significanceThus therapeutic strategies that target osteopontin signaling may be useful to treat NMO.
Journal: BBA Clinical - Volume 3, June 2015, Pages 126–134